Xontogeny

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Neurosterix is a biopharmaceutical company dedicated to developing innovative medicines for neurological disorders through a unique pharmacological approach known as allosteric modulation. This methodology aims to address the limitations of traditional treatments by enhancing the efficacy, safety, and tolerability of therapies, particularly for conditions such as schizophrenia and other neuropsychiatric disorders. Neurosterix operates a drug discovery and development platform that focuses on delivering improved treatment options for patients with underserved neurological conditions, ultimately striving to enhance the quality of life for those affected.

Delve Bio is a biotechnology company focused on delivering molecular insights for precision patient care. It specializes in the pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF) through a single test. This capability equips laboratories and clinicians with essential information for diagnosing both routine and rare infectious diseases, thereby enhancing patient care and treatment outcomes.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Peroxitech Therapeutics is a biopharmaceutical company focused on developing PIP-2, a novel peptide drug aimed at reversing acute lung injury (ALI). The company’s approach targets the cytokine storm cascade, a critical process in the development of lung injuries, particularly those resulting from oxygen deprivation. By addressing this underlying mechanism, Peroxitech aims to provide effective treatment options for patients suffering from acute lung conditions.

PolyCore Therapeutics is a biotechnology company focused on developing innovative treatments for central nervous system (CNS) disorders. The company's research specifically targets dyskinesia and cognitive impairment associated with conditions such as Parkinson's disease. PolyCore is committed to creating new, affordable therapies aimed at managing the side effects of existing treatments, which can enhance patient mobility and quality of life. By prioritizing the development of breakthrough therapeutics, PolyCore Therapeutics seeks to address significant healthcare challenges while also aiming to reduce overall healthcare costs for patients suffering from neurological diseases.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Peroxitech Therapeutics is a biopharmaceutical company focused on developing PIP-2, a novel peptide drug aimed at reversing acute lung injury (ALI). The company’s approach targets the cytokine storm cascade, a critical process in the development of lung injuries, particularly those resulting from oxygen deprivation. By addressing this underlying mechanism, Peroxitech aims to provide effective treatment options for patients suffering from acute lung conditions.

Shifa Biomedical Corporation is a biopharmaceutical company based in Malvern, Pennsylvania, that specializes in drug discovery, particularly for cardiovascular diseases. Established in 2006, the company focuses on the cost-effective development of small molecule drugs and vaccines. Shifa employs advanced techniques such as molecular biology, biochemistry, crystallography, and various screening methods to facilitate structure-based drug discovery. The organization is staffed by a highly experienced team of scientists with significant expertise in early-stage drug discovery, enabling them to support medical researchers and biotechnologists in their efforts to develop innovative treatments for cardiovascular conditions and prostate cancer.

Nephraegis Therapeutics is a biopharmaceutical company focused on the development of NPH-022, a drug designed to prevent and treat Acute Kidney Injury (AKI). The company's innovative technology is based on an epoxyeicosatrienoic-related compound that regulates various renal and vascular processes. This approach aims to protect kidney functions in patients, particularly during common cardiovascular and abdominal procedures, thereby reducing their risk of death associated with kidney complications.